Epothilone D (Kosan/Roche).
Kosan and Roche are developing the microtubule inhibitor epothilone D (KOS-862 and NSC-703147), an analog of epothilone B for the potential treatment of cancer. Phase II trials in colorectal, metastatic breast and non-small-cell lung cancers were initiated in December 2003.
Kolman
Ada
A
Department of Molecular Biology and Functional Genomics, Stockholm University, SE-106 91 Stockholm, Sweden. ada.kolman@molbio.su.se
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D034261:Epothilones / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D034261:Epothilones; C114026:desoxyepothilone B